The treatment of chronic lymphocytic leukemia (CLL) is in rapid transition, and during recent
decades both combination chemotherapy and immunotherapy have been introduced. To …

We examined the prognostic influence of gender in chronic lymphocytic leukemia. Data from
four randomized trials (involving 1821 patients) and three registration studies of stage-A …

Introduction While prognosis for patients with chronic lymphocytic leukemia (CLL) has
improved over time in younger adults, only modest improvements have occurred in older …

Clinical trials have demonstrated that rituximab improves overall survival in non-Hodgkin
lymphoma (NHL), except in mantle cell lymphoma (MCL). We used Surveillance …

Introduction. Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM) is a rare
lymphoma affecting older patients. Its management largely relies on small phase II trials and …

A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual
disease negative status after therapy. We retrospectively evaluated the impact of minimal …

Optimal treatment of chronic lymphocytic leukemia (CLL) remains unclear. The Connect CLL
Registry, a United States–based multicenter prospective observational cohort study …

The median age at diagnosis of chronic lymphocytic leukemia (CLL) is 72, but patients
enrolled in randomized trials are often a decade younger. Therapy selection and outcomes …

We report the largest retrospective, phase IV non-interventional, observational study of
ofatumumab therapy in heavily pre-treated patients with poor-prognosis chronic lymphocytic …

Despite diagnostic and therapeutic advances, the majority of patients with splenic marginal
zone lymphoma (SMZL) are still treated with splenectomy. We analyzed survival outcomes …